Category: Patent Litigation
-
Netgear settles WiFi 6 standard-essential patent dispute with Huawei, takes license to Sisvel pool between Unified Patent Court and Munich I Regional Court rulings
Netgear and Huawei have filed a motion to stay the U.S: litigation started by the router maker in response to enforcement actions in the UPC and German courts.
-
Unprecedented major delay at USITC for remedy recommendation after Lenovo was found to infringe four Ericsson SEPs
While ITC judges typically issue their recommendations on remedy (i.e., U.S. import ban) near-simultaneously with their rulings, it will now potentially take more than two months in an Ericsson-Lenovo SEP case.
-
Huawei v. Netgear was only the second UPC anti-antisuit motion this month: a near-simultaneous one may have targeted Xiaomi
The UPC’s Munich LD has now published its December 11, 2024 anti-antisuit injunction in Huawei v. Netgear. It turns out that a similar motion was brought in a different case slightly before Huawei’s filing.
-
Abbott fends off Dexcom’s push for patent royalties as multi-jurisdictional litigation settles with 10-year zero-zero patent peace over glucose monitoring devices
Abbott and Dexcom have settled a multi-jurisdictional patent dispute over glucose monitoring devices. It appears that Dexcom failed to achieve its goal of getting Abbott to pay.
-
Netgear obeys UPC and German anti-antisuit injunctions, yet attempts to thwart Huawei’s patent enforcement through interim license
Netgear has withdrawn its request for a U.S. antisuit injunction against Huawei’s UPC and German cases, but keeps pursuing an interim license.
-
UPC’s Court of Appeal throws out Alexion’s appeals against Amgen and Samsung Bioepis over validity doubts, reveals €100M value of each dispute
The UPC’s Court of Appeal rejects Alexion’s appeals of decisions to deny preliminary injunctions against Amgen and Samsung Bioepis, where the value of the dispute was set at €100M for each case.
-
Japan’s Nippon Shinyaku vows to fight on in U.S. drug dispute against Sarepta Therapeutics, despite heavy $115 million blow
The Japanese pharma company initiated the drug patent litigation in 2021, but the case eventually boomeranged and a District of Delaware verdict last week ultimately handed Sarepta the win.
-
UPC responds to first antisuit attack on its jurisdiction with first anti-antisuit injunction against Netgear; Huawei also gets one from Munich I Regional Court
Context: Last week, the Unified Patent Court’s (UPC) Munich Local Division (LD) entered a final judgment, along with a permanent injunction, for Huawei and against Netgear (December 18, 2024 ip fray article). We subsequently explained the UPC’s FRAND (fair, reasonable and non-discriminatory licensing) reasoning (December 18, 2024 ip fray article) and reported on a trial that the Landgericht München…
-
In U.S. court filing that sheds light on UPC and German cases, Huawei claims to have been “repeatedly ghosted by Netgear”
A filing made by Huawei with a U.S. court on Friday accuses Netgear of repeatedly “ghosting” the Chinese innovator when it came to discussing licensing terms.
-
Xockets’ antitrust claims against Microsoft, Nvidia and RPX may fail, but group boycott of patent holders remains overarching concern
Xockets tries to salvage its antitrust claims against Microsoft, Nvidia and RPX over an alleged conspiracy not to license or buy its patents that it claims are essential to AI.